TodayToday's FDA meeting was a lesson into why you can't predict. IMHO it became clear the single arm limited P3 results was the issue for the no vote. With such a prevliance of BC it was asked. Why is it so hard to conduct a thorough P3 study. I guess Telesta will hope February brings new life but with such an overwellming no vote it's hard to imagine MCNA will get to market without a another P3. Frankly I think another P3 is needed after listening to the Q & A today. GLTA.